文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Acute life-threatening toxicity from CAR T-cell therapy.

作者信息

Azoulay Elie, Darmon Michael, Valade Sandrine

机构信息

Médecine Intensive Et Réanimation, APHP, Hôpital Saint-Louis, Paris Diderot Sorbonne University, Paris, France.

出版信息

Intensive Care Med. 2020 Sep;46(9):1723-1726. doi: 10.1007/s00134-020-06193-1. Epub 2020 Jul 23.

DOI:10.1007/s00134-020-06193-1
PMID:32705293
Abstract
摘要

相似文献

[1]
Acute life-threatening toxicity from CAR T-cell therapy.

Intensive Care Med. 2020-9

[2]
Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy.

J Immunother Cancer. 2019-10-22

[3]
CAR T-cell therapy: toxicity and the relevance of preclinical models.

Immunotherapy. 2015

[4]
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.

Mol Cancer. 2019-8-20

[5]
Cutaneous toxicity of CAR T-cell therapy: Case report of a bullous life-threatening reaction.

J Eur Acad Dermatol Venereol. 2023-6

[6]
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites.

Cell Death Dis. 2018-9-4

[7]
Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.

Cytotherapy. 2020-2-13

[8]
Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging.

Oncotarget. 2015-9-15

[9]
Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.

J Immunother. 2018-9

[10]
Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.

Gene Ther. 2017-9-21

引用本文的文献

[1]
CAR-NK cell therapy: promise and challenges in solid tumors.

Front Immunol. 2025-4-7

[2]
RevCAR-mediated T-cell response against PD-L1-expressing cells turns suppression into activation.

NPJ Precis Oncol. 2025-2-9

[3]
Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors.

Front Immunol. 2022

[4]
Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement.

Lancet Child Adolesc Health. 2022-2

[5]
[Mechanism and prevention strategies of neurotoxicity in CAR-T treatment of B cell tumors].

Zhonghua Xue Ye Xue Za Zhi. 2021-9-14

[6]
Critical illness in patients with hematologic malignancy: a population-based cohort study.

Intensive Care Med. 2021-10

[7]
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.

Cochrane Database Syst Rev. 2021-9-13

[8]
Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.

Stem Cell Rev Rep. 2021-12

[9]
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.

Biomark Res. 2021-7-13

[10]
Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies.

Int J Mol Sci. 2020-11-17

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索